e&a in numbers: a look at our achievements
As consultants dedicated to insights and results, "to measure is to know" is more than just a saying for us at e&a – it’s part of our DNA. With this in mind, we’re proud to share our latest year report, highlighting key metrics from 2017 to now.
Dossier success rates
Our customer’s success is our success. That’s why we’re happy to share that roughly 85% of our submitted price dossiers and medicine reimbursement dossier have been successful. In most cases, this meant that the requested price was granted. In all cases, this meant that our customer was very pleased with the end result.
Focus on orphan medicines
Our team’s commitment to advancing orphan medicines is evident in our performance: a significant portion of all reimbursement dossiers we submit are for orphan medicines.
Additionally, we reviewed the MORSE (Monitoring Of Reimbursement Significant Expenses) report, issued annually by the NIHDI, and we’re proud to see that our dedication to orphan medicines is reflected in the report, compared to the total number of orphan medicine dossiers submitted.
Looking at numbers for other medicine types, the report also places us on par with – or even above – industry benchmarks.
Company growth
Finally, we’re grateful to see our client base double over the past few years and to welcome more dedicated consultants to our team. This growth only drives our passion for helping clients succeed and getting patients access to the medicines they need, and we’re looking forward to an even brighter future.
Can we support you in making your innovative medicines available to patients?
Unlocking market access in healthcare & navigating pharmacoeconomics
In today’s ever-evolving healthcare landscape, market access for new medicines and treatments is more complex than ever and pharmacoeconomics has become a critical tool. We sat down to discuss these challenges with our Managing Director Johan Eykens and Philippe Van Wilder from Smart&Bi.
Introducing our new colleague, Lena!
We’re excited to welcome Lena Dumortier as the latest addition to the e&a consultants team! Joining us as a Market Access Associate Consultant, Lena brings her passion for helping patients and her background in pharmacy.
Explaining the reformed reimbursement procedure in Belgium
In May 2024, a major reform of medicine reimbursement in Belgium was approved by the Parliament. This reform is now also published into the Belgian Official Gazette. But how will these changes impact pharma companies and patients?
Partnership in the picture: providing comprehensive support with InfarAMA
To maximise your market success, e&a consultants partners with InfarAMA, expert in regulatory affairs. Johan Eykens sat down with InfarAMA’s managing directors, Marian Coquel and Kristl Vandenbussche, to discuss the partnership’s strengths.
Market access intern Chloé on her internship at e&a consultants
After nine months, Chloé’s internship at e&a consultants has come to an end, the perfect opportunity for her to look back on the highlights and learnings of this period with her supervisor, Arne.
It’s official: the reimbursement procedure for medicine will be reformed!
Last week a major reform of the reimbursement procedure for medicine was approved. But what does that mean for you as a patient or for your pharma company? e&a consultants summarises the key points for you.
Collect your real-world data with Carebytes
In partnership with healthcare software developer Carebytes, e&a consultants has designed a real-world data platform, customisable to your needs and with GDPR compliance.
e&a consultants introduces pharma students to market access
e&a consultants co-organises an Orientation Day to introduce master pharma students at the KU Leuven to consultancy and other career paths. Why the need for this event? Managing director Johan Eykens and senior associate consultant Lotte Herbots are happy to tell you.
New colleague in the picture: meet office assistant Elodie
We could never support our clients as well as we do without our top-notch team. Meet our newest colleague, office assistant Elodie Recio Martinez.
e&a consultants looks back at 2023: new team, new platform, new laws
Managing Director Johan Eykens looks back on 2023, a year full of changes for e&a consultants. What was their greatest milestone in 2023? What are the challenges to come? Find out in this interview.
We wish you a sparkling 2024
As 2024 approaches, we are filled with excitement. Because along with the new year, a thrilling new chapter for e&a consultants begins.